PRLR and neoplasm: Importantly, in vivo studies confirm that oral administration of 4SC-202 significantly inhibits tumor growth and reduces PRLR pathway activity within the tumor tissue, with no observed significant hepatotoxicity or organ pathological damage, highlighting its excellent in vivo safety profile (118).